At the end of 2018, the FDA warned that no one, especially not men, should purchase or use two e-cigarette liquids that contain popular erectile dysfunction drugs. Because apparently, somehow, that’s an actual thing.

RELATED STORY:

Two of HelloCig e-liquids contain tadalafil and sildenafil, the main ingredients in two of the most popular male enhancement drugs on the market, and according to the FDA they have not been “approved for inclusion in e-liquid products sold over the counter and are therefore being sold illegally.”1 (Lab analysis found sildenafil and tadalafil in E-Cialis HelloCig E-Liquid and sildenafil in E-Rimonabant HelloCig E-Liquid, both sold by Shanghai-based HelloCig Electronic Technology Co. Ltd.)

The FDA said that by not properly labeling the e-liquids HelloCig failed to provide “adequate warnings for the protection of users.” Especially those with erectile dysfunction, high blood pressure, diabetes, high cholesterol or heart disease who take nitrates to manage their condition. In fact, some of the ingredients found in those two blends could “interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels.” 2

RELATED STORY:

In October, the FDA sent a warning letter to HelloCig however they have yet to respond. Part of the letter dealt with HelloCig’s illegal marketing claims, a violation of federal rules.

RELATED STORY:

Bottles of E-Cialis HelloCig E-Liquid were sold with an image of a Cialis bottle and tablets, while E-Rimonabant HelloCig E-Liquid (which contains the same active ingredient as Viagra) was marketed it with an image of an Acomplia container and tablets (an anti-obesity drug product in Europe).

Neither the manufacturers of Cialis or Viagra had any comment.

Thankfully, to date, no adverse events have been reported. The FDA has asked that any consumers using the products to stop immediately and if they do experience side effects, to report them to the FDA’s MedWatch Adverse Event Reporting program.

 

SOURCE:

  1. CNN